Radionuclides for radioimmunotherapy: criteria for selection.
In developing and designing radioimmunotherapy, the selection of the isotope is a major factor. This selection depends on a number of criteria and parameters, affecting usefulness and feasibility. Usefulness is directly related to the radiological performance of the ionising radiation in relation to tissue and its morphology, with a major distinction between the effects of alpha and beta-particles (or rays). Usefulness is also directly related to the pharmacodynamic performance of the isotope-carrier (e.g. antibody) complex, where the proper choice of isotope radiodecay halflife is of major importance. Feasibility depends on availability of the components in the isotope-ligand-carrier complex, and also on convenience and safety aspects in the preparation and the handling of the materials as well as in their application in patients. A comparison is made between the various properties of alpha-emitting isotopes that have been proposed over a number of years, concluding that the combination 225Ac- 213Bi deserves serious further attention.
Geerlings
M W
MW
Akzo nv, Arnhem, The Netherlands.
D000186:Actinium / Q000627:therapeutic use; D000512:Alpha Particles / Q000627:therapeutic use*; D001610:Beta Particles / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000627:therapeutic use
D011868:Radioisotopes; D000186:Actinium; D001729:Bismuth